Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials

被引：2
|
作者：
Gupta, Vikas [1 ]
Harrison, Claire N. [2 ]
Gorsh, Boris [3 ]
Patel, Bharat [3 ]
Wang, Zhaohui [4 ]
Purser, Molly [3 ]
Ellis, Catherine [4 ]
Strouse, Bryan [3 ]
Patnaik, Dwaipayan [5 ]
Kawashima, Jun [6 ]
Mesa, Ruben A. [7 ]
机构：
[1] Univ Hlth Network, Div Med Oncol & Hematol, Leukemia Program, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Guys & St Thomas NHS Fdn Trust, London, England
[3] GSK Plc, Collegeville, PA USA
[4] GlaxoSmithKline, Collegeville, PA USA
[5] GSK, Baar, Switzerland
[6] Sierra Oncol, San Mateo, CA USA
[7] Atrium Hlth Wake Forest Baptist Comprehens Canc C, Winston Salem, NC USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-178772
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 6 条
  • [1] Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
    Mesa, Ruben
    Harrison, Claire
    Oh, Stephen T.
    Gerds, Aaron T.
    Gupta, Vikas
    Catalano, John
    Cervantes, Francisco
    Devos, Timothy
    Hus, Marek
    Kiladjian, Jean-Jacques
    Lech-Maranda, Ewa
    McLornan, Donal
    Vannucchi, Alessandro M.
    Platzbecker, Uwe
    Huang, Mei
    Strouse, Bryan
    Klencke, Barbara
    Verstovsek, Srdan
    LEUKEMIA, 2022, 36 (09) : 2261 - 2268
  • [2] Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
    Ruben Mesa
    Claire Harrison
    Stephen T. Oh
    Aaron T. Gerds
    Vikas Gupta
    John Catalano
    Francisco Cervantes
    Timothy Devos
    Marek Hus
    Jean-Jacques Kiladjian
    Ewa Lech-Maranda
    Donal McLornan
    Alessandro M. Vannucchi
    Uwe Platzbecker
    Mei Huang
    Bryan Strouse
    Barbara Klencke
    Srdan Verstovsek
    Leukemia, 2022, 36 : 2261 - 2268
  • [3] Time-Dependent Transfusion Status as an Independent Predictor of Overall Survival: A Post Hoc Analysis of 3 Phase 3 Trials
    Gupta, Vikas
    Harrison, Claire
    Gorsh, Boris
    Patel, Bharat
    Wang, Zhaohui
    Purser, Molly
    Ellis, Catherine
    Strouse, Bryan
    Patnaik, Dwaipayan
    Kawashima, Jun
    Mesa, Ruben
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S410 - S410
  • [4] Time without Transfusion Reliance or Anemia Worsening: A Novel Method for Integrating Transfusion Dependence, Anemia, and Survival with Myelofibrosis Therapies Based on the Phase 3 Simplify-1 and Simplify-2 Trials
    Mesa, Ruben A.
    Talpaz, Moshe
    Mazerolle, Flora
    Gorsh, Boris
    M'Hari, Manal
    Regnault, Antoine
    Ellis, Catherine
    Wang, Zhaohui
    Purser, Molly
    Liu, Tom
    Strouse, Bryan
    Patnaik, Dwaipayan
    BLOOD, 2023, 142
  • [5] Transfusion Intensity Over Time in Patients From the Phase 3 SIMPLIFY-1 and MOMENTUM Trials of Momelotinib
    Mesa, Ruben
    Perkins, Andrew
    Goh, Yeow Tee
    Fox, Maria Laura
    McLornan, Donal
    Palmer, Jeanne
    Foltz, Lynda
    Vannucchi, Alessandro
    Koschmieder, Steffen
    Passamonti, Francesco
    Lee, Sung Eun
    Kawashima, Jun
    Strouse, Bryan
    Carreras, Francisco Gonzalez
    Oh, Stephen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S411 - S411
  • [6] Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required Red Blood Cell Transfusions: Subgroup Analysis of the Phase 3 SIMPLIFY-2 Study
    Harrison, Claire
    Scheid, Christoph
    Vannucchi, Alessandro M.
    Recher, Christian
    Passamonti, Francesco
    Gerds, Aaron T.
    Hernandez-Boluda, Juan Carlos
    Yacoub, Abdulraheem
    Sirhan, Shireen
    Kawashima, Jun
    Patel, Bharat
    Strouse, Bryan
    Platzbecker, Uwe
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 118 - 118
1